CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
HYPOXIMMUNO aims to enhance lung cancer treatment by combining immunotherapy with advanced imaging and targeted therapies for hypoxic tumor cells. The project focuses on developing a tri-modal treatment strategy to improve patient outcomes in metastatic non-small cell lung cancer.
Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually and it places the highest economic burden of all cancers on the EU at €18.8billion.
These figures call for a major transformation of the therapeutic management of lung cancer.
The recent developments in immunotherapy give new hope.
At present a significant minority of patients benefit from immune therapy, which remains not curative when delivered alone.
It is thus clear that improving the effica…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Montpellier Cedex 5
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
